{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+Rejection+in+Kidney+Transplant&page=2", "query": { "condition": "Prevention of Rejection in Kidney Transplant", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+Rejection+in+Kidney+Transplant&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prevention+of+Rejection+in+Kidney+Transplant&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T00:15:40.785Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00235300", "title": "An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cadaveric Donor Renal Transplantation", "Acute Renal Allograft Rejection", "Induction Therapy" ], "interventions": [ { "name": "Thymoglobulin [Anti-thymocyte Globulin (rabbit)]", "type": "BIOLOGICAL" }, { "name": "Simulect (basliximab)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2000-05", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2015-03-18", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235300" }, { "nct_id": "NCT06126380", "title": "Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Rejection" ], "interventions": [ { "name": "AT-1501", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eledon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 132, "start_date": "2023-10-25", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 26, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126380" }, { "nct_id": "NCT07290777", "title": "VEL-101 to Prevent Rejection After Kidney Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplantation, Kidney" ], "interventions": [ { "name": "Tacrolimus (TAC)", "type": "DRUG" }, { "name": "VEL-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-08-18", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290777" }, { "nct_id": "NCT00363116", "title": "A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 298, "start_date": "1999-04", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2013-10-25", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 23, "location_summary": "Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363116" }, { "nct_id": "NCT05027906", "title": "Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prevention of Rejection in Kidney Transplant" ], "interventions": [ { "name": "AT-1501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eledon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 48, "start_date": "2022-02-18", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027906" }, { "nct_id": "NCT01095887", "title": "Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Eculizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-07-20", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01095887" }, { "nct_id": "NCT01187953", "title": "Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "Prograf (tacrolimus)", "type": "DRUG" }, { "name": "LCP-Tacro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veloxis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 543, "start_date": "2010-09", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacremento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01187953" }, { "nct_id": "NCT01154387", "title": "Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "End Stage Renal Disease", "Renal Transplant" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "TOL101", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tolera Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 85, "start_date": "2010-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-06-11", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 12, "location_summary": "Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154387" }, { "nct_id": "NCT05156710", "title": "BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplant Rejection" ], "interventions": [ { "name": "BIVV020 (SAR445088)", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIg)", "type": "DRUG" }, { "name": "Rituximab or biosimilar", "type": "DRUG" }, { "name": "Antithymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-06-09", "completion_date": "2026-10-20", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156710" }, { "nct_id": "NCT04046549", "title": "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allografts", "Rejection; Transplant, Kidney", "Transplant Rejection", "Kidney Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "VIB4920", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 25, "start_date": "2019-10-30", "completion_date": "2023-03-22", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-06T00:15:40.785Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046549" } ] }